Factor Xa Antidote Decoy Neutralizes Inhibitors Without Thrombosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulant therapies, particularly those targeting factor Xa, face limitations in safely reversing anticoagulation effects, especially in cases of overdose or surgical emergencies, due to the lack of specific and effective antidotes that do not cause thrombosis.
Innovation Solution
Development of modified factor X protein derivatives with reduced or eliminated intrinsic procoagulant activity, which can bind and neutralize factor Xa inhibitors without assembling into the prothrombinase complex, thereby serving as safe antidotes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant factor VIIa is used to reverse fXa inhibitors, then some anticoagulant effect can be restored, but the antidote effect is limited and cannot achieve complete neutralization due to mechanistic constraints
Solution Approach 1:
The patent extracts only the inhibitor-binding capability from factor Xa while removing the procoagulant catalytic function through active site mutations (e.g., S195A, H57A, D102A). This creates a decoy molecule that binds fXa inhibitors with high affinity but cannot assemble into functional prothrombinase complexes or convert prothrombin to thrombin, thereby achieving complete neutralization without thrombotic risk.
Solution Approach 2:
The mutated factor Xa derivatives serve as intermediary molecules that mediate between the fXa inhibitor and the coagulation system. These derivatives bind the inhibitors with high affinity, acting as decoys that prevent the inhibitors from interacting with endogenous factor Xa, thereby restoring normal hemostasis without directly activating coagulation.
2Reliability
If factor Xa inhibitors are used for anticoagulant therapy, then thrombosis prevention is achieved, but the ability to rapidly reverse anticoagulation is limited due to lack of specific antidotes
Solution Approach 1:
The patent develops antidote molecules in advance that are specifically designed to neutralize fXa inhibitors. These mutated factor Xa derivatives are prepared beforehand with known high affinity for various fXa inhibitors, enabling rapid administration and neutralization when reversal is needed, without requiring complex in-hospital preparation or monitoring of multiple parameters.
3Reliability
If active factor Xa is administered as antidote, then procoagulant activity is restored, but thrombosis risk increases due to potent enzyme activity
Solution Approach 1:
The patent extracts only the inhibitor-binding capability from factor Xa while removing the procoagulant catalytic function through active site mutations (e.g., S195A, H57A, D102A). This creates a decoy molecule that binds fXa inhibitors with high affinity but cannot assemble into functional prothrombinase complexes or convert prothrombin to thrombin, thereby achieving complete neutralization without thrombotic risk.
Solution Approach 2:
The patent converts the potentially harmful procoagulant activity of factor Xa into a beneficial property by creating mutated derivatives that bind inhibitors with high affinity but lack catalytic function. This transforms what would be a thrombotic risk into a safe and effective neutralization mechanism, where the high affinity for inhibitors becomes the therapeutic advantage rather than a hazard.
Data Source
Figure 1~3
Figure 4~5
Figure 6~7
AI summary
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.